Biora Therapeutics, Inc., a clinical-stage biotechnology company based in Delaware, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on April 8, 2024. The registration is for the resale of up to 10,700,846 shares of common stock by a selling stockholder. These shares include those issuable upon conversion of convertible senior secured notes due 2028, in respect of interest payments or make-whole amounts on these notes, and upon the exercise of warrants. Biora Therapeutics will not receive any proceeds from the sale of shares by the selling stockholder, except for any cash proceeds from the exercise of warrants at $2.75 per share. The company's common stock is quoted on The Nasdaq Global Market under the symbol 'BIOR.' As of April 5, 2024, the stock was trading at $0.72 per share. The selling stockholder may sell the shares from time to time based on market conditions and other factors, through various methods including direct sales or through broker-dealers.

Biora Therapeutics, Inc., a clinical-stage biotechnology company based in Delaware, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on April 8, 2024. The registration is for the resale of up to 10,700,846 shares of common stock by a selling stockholder. These shares include those issuable upon conversion of convertible senior secured notes due 2028, in respect of interest payments or make-whole amounts on these notes, and upon the exercise of warrants. Biora Therapeutics will not receive any proceeds from the sale of shares by the selling stockholder, except for any cash proceeds from the exercise of warrants at $2.75 per share. The company's common stock is quoted on The Nasdaq Global Market under the symbol 'BIOR.' As of April 5, 2024, the stock was trading at $0.72 per share. The selling stockholder may sell the shares from time to time based on market conditions and other factors, through various methods including direct sales or through broker-dealers.